Global reach
The company is in the process of obtaining Emergency Use Listing (EUL) from the World Health Organization, and is in constant dialogue with the global health agency, responding to its requests for additional data on Covaxin. The Technical Advisory Group of the WHO is slated to review the data on October 26 to decide on its application for EUL.
It is also making efforts to get approval from the US Food and Drug Administration (USFDA) through its US partner, Ocugen. Published on October 21, 2021 |